A LAG-3, Op­di­vo com­bo from Bris­tol-My­ers of­fers a proof-of-con­cept glimpse of lim­it­ed suc­cess

CHICA­GO — Now that the first wave of PD-(L)1 drugs has splashed out and is get­ting es­tab­lished in the can­cer mar­ket, one of the next steps down the pipeline in­volves match­ing up check­point in­hibitors in new com­bos as the lead­ers in the field pur­sue a fast and fu­ri­ous R&D strat­e­gy to mar­ket ex­pan­sion. To that end, Bris­tol-My­ers Squibb $BMY turned up at AS­CO with some in­trigu­ing proof-of-con­cept da­ta that mar­ries their drug Op­di­vo with a LAG-3 drug, of­fer­ing an ear­ly glimpse on how it could work for a par­tic­u­lar cat­e­go­ry of pa­tient.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER